Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-14
2011-06-14
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S167000, C548S256000, C514S359000
Reexamination Certificate
active
07960409
ABSTRACT:
The instant invention provides compounds of Formula I which are leukotriene biosynthesis inhibitors.Compounds of Formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
REFERENCES:
patent: 5552437 (1996-09-01), Delorme et al.
patent: 2006/0116406 (2006-06-01), Gareau et al.
patent: 2007/0149579 (2007-06-01), Blouin et al.
patent: 2125824 (1994-12-01), None
patent: 2167317 (1995-02-01), None
patent: WO2007/016784 (2007-02-01), None
Ducharme Yves
Frenette Richard
Friesen Richard
Gagnon Marc
Gareau Yves
Anderson Rebecca L
Camara Valerie J.
Merck Sharp & Dohme Corp.
Shterengarts Samantha L
Yang Mollie M.
LandOfFree
Pharmaceutical phenylquinoline and chromen-2-one triazole... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical phenylquinoline and chromen-2-one triazole..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical phenylquinoline and chromen-2-one triazole... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2711120